TT01001

Research use only, not for human use.

TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.

TT01001 is a selective agonist of mitoNEET and reduces oxidative stress injury and neuronal apoptosis by improving mitochondrial dysfunction. TT01001 can be used in studies about the treatment of type II diabetes.(In Vivo):In type II diabetes model db/db mice, TT01001 improved hyperglycemia, hyperlipidemia, and glucose intolerance, and its efficacy was equivalent to that of pioglitazone, without the pioglitazone-associated weight gain. Mitochondrial complex II + III activity of the skeletal muscle was significantly increased in db/db mice. TT01001 significantly suppressed the elevated activity of the complex II + III.

TT-01001; TT 01001; Ethyl 4-(3-(3,5-dichlorophenyl)thioureido)piperidine-1-carboxylate

Others

Other Targets

RIP2

——

——

1022367-69-6

376.3

C15H19Cl2N3O2S

>98% (HPLC)

——

CCOC(=O)N1CCC(CC1)NC(=S)Nc1cc(Cl)cc(Cl)c1

——

(-20℃)

With Ice Pack

≥ 2 years